dc.contributor.author | Bringeland, Gerd Haga | |
dc.contributor.author | Myhr, Kjell-Morten | |
dc.contributor.author | Vedeler, Christian A. | |
dc.contributor.author | Gavasso, Sonia | |
dc.date.accessioned | 2021-05-31T11:55:04Z | |
dc.date.available | 2021-05-31T11:55:04Z | |
dc.date.created | 2021-01-21T14:09:02Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1302-1664 | |
dc.identifier.uri | https://hdl.handle.net/11250/2757071 | |
dc.description.abstract | Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between low natalizumab receptor occupancy and subjective wearing-off symptoms at the end of the 4-week dosing interval. Here, we aimed to evaluate the short-term risk of disease activity in a 1-year prospective follow-up of the same patient cohort (n = 40). We found that all patients available for follow-up after one year (n = 35) fulfilled the criteria for no evidence of disease activity (NEDA). Thus, wearing-off symptoms were not associated with increased short-term risk of disease activity. Longer follow-up in a larger patient cohort is required to establish whether therapeutic efficacy is maintained in patients with wearing-off symptoms. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2020 The Authors | en_US |
dc.source.articlenumber | 116880 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1016/j.jns.2020.116880 | |
dc.identifier.cristin | 1876632 | |
dc.source.journal | Journal of Neurological Sciences | en_US |
dc.identifier.citation | Journal of Neurological Sciences. 2020, 415, 116880. | en_US |
dc.source.volume | 415 | en_US |